WEBULL
News
BCRX
7.63
-0.91%
-0.07
BioCryst Pharmaceuticals (BCRX) Is Up 8.0% After FDA Clears First Oral HAE Prophylaxis For Children
Simply Wall St · 3d ago
Astria Therapeutics to Be Acquired by BioCryst Pharmaceuticals
Reuters · 5d ago
BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares
Reuters · 5d ago
TD Cowen Reaffirms Their Buy Rating on BioCryst (BCRX)
TipRanks · 5d ago
Weekly Report: what happened at BCRX last week (1215-1219)?
Weekly Report · 6d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (BCRX), Wave Life Sciences (WVE) and Alkermes (ALKS)
TipRanks · 12/18 15:30
BioCryst (BCRX) Valuation After FDA Expands ORLADEYO Access for Young Hereditary Angioedema Patients
Simply Wall St · 12/18 03:21
The Bull Case For BioCryst (BCRX) Could Change Following FDA Approval Of Pediatric ORLADEYO Pellets
Simply Wall St · 12/17 00:38
BioCryst Chief Legal Officer Alane P. Barnes Reports Disposal of Common Shares
Reuters · 12/16 21:13
BioCryst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 12/15 15:58
BioCryst Pharmaceuticals Price Target Raised to $32.00/Share From $30.00 by HC Wainwright & Co.
Dow Jones · 12/15 15:58
HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Raises Price Target to $32
Benzinga · 12/15 15:48
BioCryst’s Orladeyo Pediatric Approval and Strategic Expansion Drive Buy Rating
TipRanks · 12/15 14:15
BioCryst price target raised to $32 from $30 at H.C. Wainwright
TipRanks · 12/15 14:11
BIOCRYST PHARMACEUTICALS, INC. <BCRX.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $32 FROM $30
Reuters · 12/15 14:04
Weekly Report: what happened at BCRX last week (1208-1212)?
Weekly Report · 12/15 09:53
U.S. RESEARCH ROUNDUP-Applied Materials, Coca-Cola, Glacier Bancorp
Reuters · 12/15 08:11
BioCryst’s Avoralstat Study: A New Hope for Diabetic Macular Edema?
TipRanks · 12/14 16:38
Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioCryst (BCRX), Arcus Biosciences (RCUS) and Amicus (FOLD)
TipRanks · 12/14 13:40
Does BioCryst’s DCF and Sales Multiple Suggest a Bargain After Recent HAE Progress?
Simply Wall St · 12/13 21:22
More
Webull provides a variety of real-time BCRX stock news. You can receive the latest news about Biocryst Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.